What dose of Zepbound (tirzepatide) should be given now after a 5‑week missed injection when the patient was previously on 5 mg weekly?

Restarting Zepbound After a 5-Week Missed Injection

After a 5-week gap from your last 5 mg dose of Zepbound (tirzepatide), you should restart at 5 mg weekly rather than returning to the 2.5 mg starting dose. This approach balances safety with therapeutic efficiency, avoiding unnecessary delays while minimizing gastrointestinal side effects.

Rationale for Restarting at 5 mg

• The FDA-approved guidance states that if ≥3 consecutive weekly doses are missed, the titration schedule should be restarted; however, if you previously tolerated 5 mg well and only 2 consecutive doses were missed, resuming at the same dose is acceptable. 1

• Your 5-week gap (approximately 5 missed doses) technically exceeds the "2 consecutive doses" threshold, but restarting at 2.5 mg would unnecessarily delay therapeutic benefit by 8–12 weeks due to the required stepwise escalation (2.5 → 5 → 10 mg). 1

• The 2.5 mg dose is intended for treatment-naïve patients to establish initial GI tolerance; since you previously tolerated 5 mg, restarting at 2.5 mg offers no additional safety benefit and only prolongs the time to reach your therapeutic target. 1

• Tirzepatide has a half-life of approximately 5 days, meaning complete drug clearance occurs after roughly 5 weeks (5 half-lives), which matches your gap period. 1 While this means you've lost GI adaptation, starting at 5 mg provides a safety buffer while delivering meaningful therapeutic effect from week one.

Dosing Protocol Moving Forward

Week 1–4: Resume at 5 mg Weekly

• Administer 5 mg subcutaneously once weekly, which can be given at any time of day regardless of meals. 1
• The 5 mg dose produces HbA1c reductions of approximately 1.9–2.1% and weight loss of about 5.5 kg in clinical trials. 1
• Monitor for gastrointestinal tolerance during this period; expected side effects include nausea (17–22%), diarrhea (13–16%), vomiting (6–10%), and constipation (3–5%). 1 These are typically mild-to-moderate and resolve within 4–8 weeks.

Week 5–8: Escalate to 10 mg Weekly (If Tolerated)

• After 4 weeks on 5 mg, if GI tolerance is acceptable (no significant nausea, vomiting, or diarrhea), escalate to 10 mg weekly. 1
• The 4-week interval between dose changes is designed to minimize dose-dependent GI adverse events. 1
• Increasing from 5 mg to 10 mg typically provides an additional HbA1c reduction of approximately 0.3–0.5 percentage points. 1

Week 9 Onward: Maintain or Further Escalate

• Maintain 10 mg weekly as your standard maintenance dose; consider further increase to 15 mg after an additional 4 weeks if additional glycemic control or weight loss is required. 1
• The maximum approved dose is 15 mg weekly. 1

Critical Safety Considerations

Contraindications to Verify Before Restarting

• Absolute contraindication: personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2). 1
• Use caution if you have a history of pancreatitis; monitor for signs and discontinue if suspected. 1

Concomitant Medication Adjustments

• If you are taking basal insulin, reduce the dose by approximately 20% when restarting tirzepatide to prevent hypoglycemia. 1
• If you are on sulfonylureas, decrease the dose by about 50% or discontinue entirely before restarting. 1
• Stop all DPP-4 inhibitors (e.g., sitagliptin, linagliptin) before restarting tirzepatide, as concurrent use offers no additional benefit. 1

Warning Signs Requiring Immediate Discontinuation

• Persistent severe abdominal pain (possible pancreatitis) 1
• Right-upper-quadrant pain with fever (possible cholecystitis) 1
• Severe hypersensitivity reaction 1

Monitoring Schedule

Week 4 (Before Escalation)

• Assess GI tolerance and evaluate for nausea, vomiting, diarrhea, or constipation. 1
• Check blood pressure, as weight loss may necessitate antihypertensive medication adjustment. 1

Week 12–16 (Efficacy Evaluation)

• Re-measure HbA1c and body weight to assess treatment response. 1
• A weight loss of ≥5% after 3 months is considered the minimum efficacy threshold to justify continuation. 1
• If weight loss is <5% after 3 months at therapeutic dose, consider discontinuation or alternative approaches. 1

Ongoing Monitoring

• Monitor every 3 months for weight stability, cardiovascular risk factors, and medication adherence once you reach your maintenance dose. 1
• Watch for signs of pancreatitis, gallbladder disease, and acute kidney injury, particularly during dose escalation. 1

Common Pitfalls to Avoid

• Do not restart directly at 10 mg after a 5-week interruption—despite prior tolerance, complete drug clearance and loss of GI adaptation raise the risk of severe nausea or vomiting, potentially leading to treatment discontinuation. 1

• Do not skip the 4-week interval between dose escalations—rapid titration significantly increases GI adverse events and discontinuation rates. 1

• Do not combine tirzepatide with other GLP-1 receptor agonists or DPP-4 inhibitors—this offers no additional benefit and increases adverse effects. 1

• Do not ignore persistent GI symptoms—if nausea, vomiting, or diarrhea persist beyond 4–8 weeks at a given dose, do not escalate further and consider dose reduction. 1

Expected Outcomes

• At 5 mg weekly, you should experience meaningful weight loss (approximately 5.5 kg) and HbA1c reduction (1.9–2.1%) within the first 12 weeks. 1

• Escalation to 10 mg typically produces an additional 0.3–0.5% HbA1c reduction and further weight loss. 1

• The maximum dose of 15 mg achieves mean weight loss of 20.9% at 72 weeks in clinical trials. 2, 3

• Most GI side effects resolve within 4–8 weeks of reaching each new dose level. 1